$OPCH

OPCH shares jump 34% as CD&R, McKesson agree to $5.8B takeover

Option Care Health (OPCH) shares surged 34% after CD&R and McKesson agreed to acquire it for $32.05 per share, valuing the company at $5.8B including debt. CD&R will hold 51% stake, McKesson 49%.

Original reporting
Published Oct 6, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 1:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
OPCH shares jump 34% as CD&R, McKesson agree to $5.8B takeover — source image
Decision brief

The 30-second read

$OPCHBullishHigh
01

Why it matters

The acquisition creates a vertically integrated platform, potentially improving cost efficiencies and market reach.

02

Market read

The deal is a material M&A event in the U.S. healthcare sector, prompting a sharp stock rally and potential ripple effects for peers.

03

What to watch

Financing terms and post‑closing performance of the combined entity are not disclosed.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Option Care Health provides home health and hospice services; CD&R is a private equity firm and McKesson a large healthcare distributor.

Company-level read

Ticker impact

$OPCHBullishHigh confidence
Context

Option Care Health announced a definitive $5.8B acquisition by CD&R and McKesson, driving a 34% share jump.

Expected impact

upward pressure as market prices in the acquisition premium.

Evidence & confidence

First report of the transaction, sizable premium and immediate 34% price move.

Market effects

Consolidation in the home health services sector may prompt valuation reassessments for peers.

U.S. healthcare market sees increased M&A activity, potentially boosting related REITs.

Limited to U.S. healthcare investors; no broader macro effect.

Counterpoint

Deal could face regulatory scrutiny or integration risk, which may temper the rally.

Key entities

  • Option Care Health

    Target of the $5.8B acquisition.

  • CD&R

    Majority stakeholder acquiring ~51% of OPCH.

  • McKesson

    Minority investor acquiring ~49% of OPCH.

Related articles

$MCKLow

Built and Bred

McKesson (MCK) will invest $179M in a 330,000 sq. ft. regional distribution center in Moore, Oklahoma, creating 200+ jobs. The site's location, readiness, and regional coordination influenced the decision, according to the company.

$OPCHMed

Key deals this week: Option Care Health, PTC, Energy Transfer and more

Service Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.

$OPCHHighAI 9/10

Option Care Health Sold for $5.8B in CD&R-McKesson Deal

Option Care Health (OPCH) is being acquired by CD&R and McKesson (MCK) for $5.8B, or $32.05 per share, a 37% premium. The deal, expected to close in 2027, values the company at $5.8B. Option Care Health will operate independently post-acquisition. The company reported $5.6B in 2025 revenue and $207.6M in net income, with modest growth in 2026. The acquisition aligns with McKesson's strategy to expand access to innovative therapies.

$MCKHighAI 9/10

McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?

McKesson (MCK) is acquiring Option Care Health (OPCH) for $5.8B, including debt, at $32.05 per share, a 37% premium. McKesson and private equity firm CD&R will own 49% and 51% respectively. The deal expands McKesson's specialty healthcare services. McKesson's Q1 2027 revenue was $105.4B, beating estimates, with adjusted EPS up 20% YoY to $9.93. The company raised its fiscal 2027 adjusted EPS guidance to $44.20-$45.00.